This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ISRG vs. MDT: Which Robotic Surgery Stock Is a Smarter Buy Now?
by Indrajit Bandyopadhyay
Intuitive Surgical or Medtronic -- who leads the future of robotic surgery? Here's a comparative analysis to help you make a smart choice for 2025.
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
by Urmimala Biswas
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended April 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
by Zacks Equity Research
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 2.53% and 1.08%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Continue to Hold Medtronic Stock in Your Portfolio Now?
by Zacks Equity Research
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 387.10% and 139.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ISRG Stock Gains More than 8% YTD: Will the Uptrend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's shares seem to recover after declining more than 30% in nearly two months. Is it the right time to invest?
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session.
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates
by Zacks Equity Research
Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of 128.10% and 2.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Reports for Microsoft, Amazon.com & Mastercard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Amazon.com, Inc. (AMZN) and Mastercard Inc. (MA), as well as a micro-cap stock CBL & Associates Properties, Inc. (CBL).
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of 23.19% and 8.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.62, denoting a +0.55% change from the preceding trading day.
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch
by Urmimala Biswas
Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth.
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.54% and 2.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
by Urmimala Biswas
Despite trade policy challenges, Abbott's global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $84.85, moving +1.54% from the previous trading session.
Medtronic (MDT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $84.76, signifying a +0.19% move from its prior day's close.
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
by Zacks Equity Research
Abbott Laboratories, Boston Scientific and Medtronic are included in this Analyst Blog.
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Medtronic (MDT) reachead $84.30 at the closing of the latest trading day, reflecting a +0.66% change compared to its last close.
Medtronic (MDT) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $83.75, representing a +0.46% change from its previous close.
ISRG Q1 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Intuitive Surgical's first-quarter results are likely to reflect solid performance in the company???s Instruments & Accessories segment. Improving margins buoy optimism.
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $82.60, signifying a -0.12% move from its prior day's close.